Enasidenib for Patients w/o IDH2 Mutation
A Phase Ib/II, Single Center, Open-Label, Safety and Efficacy Study to Improve Anemia in Subjects on Enasidenib With Lower Risk Myelodysplastic Syndrome and Non-proliferative Chronic Myelomonocytic Leukemia Without an IDH2 Mutation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 48 patients (estimated)
- Sponsors
- Stanford Cancer Institute
- Collaborators
- Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb
- Tags
- IDH2 Inhibitor
- Trial Type
- Supportive
- Last Update
- 2 weeks ago
- SparkCures ID
- 1596
- NCT Identifier
- NCT05282459
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.